Pfizer Inc (MIL:1PFE)
€ 24.625 -0.16 (-0.65%) Market Cap: 138.78 Bil Enterprise Value: 192.52 Bil PE Ratio: 34.89 PB Ratio: 1.59 GF Score: 64/100

Pfizer Inc Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Transcript

Dec 17, 2021 / 01:30PM GMT
Operator

Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to discuss the Pfizer-BioNTech COVID-19 vaccine and Pfizer's novel COVID-19 oral antiviral treatment candidate. Today's call is being recorded.

At this time, I would like to turn the call over to Mr. Chris Stevo, Senior Vice President and Chief Investor Relations Officer. Please go ahead, sir.

Christopher J. Stevo
Pfizer Inc. - Senior VP & Chief IR Officer

Thank you, Sophia. Good morning, everyone. I'd like to welcome you all to Pfizer's investor event to discuss our COVID-19 vaccines and therapeutics franchise.

Presentation at today's investor event includes forward-looking statements about, amongst other things, our efforts to combat COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitors, our anticipated future operating and financial performance, business plans and prospects and expectations for our in-line products and product candidates.

By their nature, all statements about future events and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot